Germany’s BioNTech is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and the Gilead company’s clinical manufacturing plant in Gaithersburg, Maryland.

Boston-based Alexion Pharmaceuticals announced positive topline data from the company’s Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.

Australian scientists say they have developed the “holy grail” of blood sugar testing for diabetics, a non-invasive strip that checks glucose levels via saliva.

Los Angeles-based biopharmaceutical firm Enochian BioSciences received a green light from the U.S. Food and Drug Administration for feedback on a possible cure for infections caused by the hepatitis B virus (HBV).

Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.

A third shot of the Oxford-AstraZeneca Covid-19 vaccine produces a strong immune response, researchers said on June 28, adding there was not yet evidence that such shots were needed, especially given shortages in some countries.

AbbVie exercised an exclusive right to acquire TeneoOne, an affiliate of TeneoBio, and the company’s lead asset TNB-383B for relapsed or refractory multiple myeloma (R/R MM). 

A study from the Icahn School of Medicine at Mount Sinai shows how cancer can fool immune cells, which normally repair the body, into actually helping develop the disease. 

Novartis AG received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer, the Swiss drugmaker said on June 16.

Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.